Research updateFunctional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets
Graphical abstract
Section snippets
Pharmacological and drug-discovery implications of functional selectivity
According to the tenets of the traditional “two-state” model of G protein-coupled receptor (GPCR) function, a GPCR acts as a ligand-controlled “on-off” switch, eliciting, when activated by an agonist, a cascade of cellular signals and effects through specific transducers such as G proteins without any particular directionality to the ensuing information output [1]. Based upon data from an array of biophysical and biochemical studies, this outmoded paradigm has been elaborated to a so-called
Receptor-mediated cannabinoid physiology
The endogenous cannabinoid (“endocannabinoid”) system includes two principal class-A GPCRs: cannabinoid receptor 1 (CB1R), predominantly expressed in the brain [25] and to a lesser extent in the periphery [26], and cannabinoid receptor 2 (CB2R), expressed mainly in immune cells and during inflammatory injury in the central nervous system (CNS) [27]. CB2R has 44% overall sequence identity with CB1R and shows comparatively greater interspecies heterogeneity. Some 25 years ago, identification and
Functional selectivity at CB1R
All endocannabinoid signaling lipids, including the principal, arachidonic acid-derived mediators found in mammals, anandamide (AEA) (4, Fig. 2) and 2-arachidonoylglycerol (2-AG) (5, Fig. 2), preferentially activate Gi/o G proteins at CB1R (Table 1). Certain structurally distinct cannabinergic ligands, upon binding to CB1R, can elicit the receptor’s differential interaction with Gi and/or Go G-protein subtypes. HU210 (6, Fig. 2) activates both Gi and Go proteins to maximal efficacy, whereas
Functional selectivity at CB2R
Reminiscent of CB1R, CB2R can be activated by cannabinergic agents that signal differentially through various intracellular information pathways in a ligand-dependent manner (Table 2). CB2R preferably interacts with Gi over Go, the latter not widely expressed in the peripheral tissues where CB2R expression is high. Furthermore, at CB2R, HU210 produces a maximal Gi response unlike AEA, which produces a partial response [56]. At CB2R, low concentrations of CP55940 inhibit adenylyl cyclase and
Structural basis for signaling bias at cannabinoid GPCRs
Exponential progress in atomic-level structure determination of membrane proteins in the last few years has enabled the crystal structures of some 30 unique GPCRs, and over 119 different GPCR structures have been solved [68]. These structures have improved our understanding of the GPCR conformational states associated with (especially orthosteric) ligand engagement as they pertain to various activity states. The large outward displacement of transmembrane helix (TMH) 6 and inward movement of
Pharmacotherapeutic implications of biased signaling at CBRs
As a component of its overall pharmacological profile, the ability of a GPCR-targeted therapeutic candidate to activate differentially specific intracellular effector pathways carries critical implications for drug discovery. For example, niacin acts therapeutically as an antilipolytic agent by activating GPR109A receptor-mediated G-protein signaling. However, it also activates the G protein-independent β-arrestin1 pathway responsible for cutaneous flushing and other adverse effects [86].
Future research directions
Although it is well established that most GPCR ligands may exhibit pluridimensional efficacies with respect to different signaling pathways, challenges remain in the study of CBR functional selectivity. Experimental nuances such as kinetics of response, response read-out bias, cell/tissue-specific variations, and the system-dependency of the observed pharmacological effects may influence the qualitative nature of biased signaling and its quantification [98]. Stereochemical [65] and
Note added in proof
While this publication was in press, a review of ligand bias at CB1R/CB2R in the context of the central nervous system was published [123]. A new, high-resolution crystal structure of a liganded CB1R construct bound to the drug taranabant has also appeared in the literature [124] that offers some additional orthosteric ligand-docking predictions as compared to the previously-reported [77] CB1R X-ray structure.
Conflict of interest
The authors declare no conflicts of interest regarding the subject of this paper.
References (124)
- et al.
A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor
J. Biol. Chem.
(1980) - et al.
Conformational complexity of G-protein-coupled receptors
Trends Pharmacol. Sci.
(2007) - et al.
The role of protein dynamics in GPCR function: insights from the β2AR and rhodopsin
Curr. Opin. Cell Biol.
(2014) The many faces of G protein signaling
J. Biol. Chem.
(1998)- et al.
The G protein-coupled receptor kinase (GRK) interactome: Role of GRKs in GPCR regulation and signaling
Biochim. Biophys. Acta BBA - Biomembr.
(2007) Ion-channel regulation by G proteins
Trends Endocrinol. Metab.
(2001)- et al.
Functional selectivity of dopamine D1 receptor agonists in regulating the fate of internalized receptors
Neuropharmacology
(2007) - et al.
Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7
J. Biol. Chem.
(2004) - et al.
Therapeutic potential of β-arrestin- and G-protein-biased agonists
Trends Mol. Med.
(2011) - et al.
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action
Trends Neurosci.
(1998)
Effects of cannabinoids on energy metabolism
Life Sci.
The role of endocannabinoids in the hypothalamic regulation of visceral function
Prostaglandins Leukot. Essent. Fatty Acids
AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis
Eur. J. Pharmacol.
Cannabinoids and ceramide: two lipids acting hand-by-hand
Life Sci.
Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons
J. Biol. Chem.
Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects
Pharmacol. Biochem. Behav.
Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB2 receptor inverse agonists
Chem. Biol.
Emerging structural insights into biased GPCR signaling
Trends Biochem. Sci.
Ligand binding and micro-switches in 7TM receptor structures
Trends Pharmacol. Sci.
Crystal structures of a stabilized β1-adrenoceptor bound to the biased agonists bucindolol and carvedilol
Struct. Lond. Engl.
The extracellular surface of the GLP-1 receptor is a molecular trigger for biased agonism
Cell
Structural mimicry in class A GpProtein-coupled receptor rotamer toggle switches. The importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation
J. Biol. Chem.
A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor
J. Biol. Chem.
Biased agonism at kappa opioid receptors: implication in pain and mood disorders
Eur. J. Pharmacol.
β-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner
Biol. Psychiatry
The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals
J. Cell Sci.
Not so strange bedfellows: G-protein-coupled receptors and Src family kinases
Oncogene
Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus
Mol. Pharmacol.
Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist
Br. J. Pharmacol.
Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance
Pharmacol. Rev.
Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase
J. Pharmacol. Exp. Ther.
Functionally selective dopamine D2, D3 receptor partial agonists
J. Med. Chem.
Functional selectivity of melanocortin 4 receptor peptide and nonpeptide agonists: evidence for ligand-specific conformational states
J. Pharmacol. Exp. Ther.
Quantification of functional selectivity at the human α1A-adrenoceptor
Mol. Pharmacol.
Structural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptor
J. Mol. Endocrinol.
Gonadotropin-releasing hormone receptor signaling: biased and unbiased
Mini Rev. Med. Chem.
β-arrestin-biased agonism at the parathyroid hormone receptor uncouples bone formation from bone resorption
Endocr. Metab. Immune Disord. Drug Targets
Molecular michanism of β-arrestin-biased agonism at seven-transmembrane receptors
Annu. Rev. Pharmacol. Toxicol.
Minireview: more than just a hammer: ligand ’bias’ and pharmaceutical discovery
Mol. Endocrinol.
Biased agonism at G protein-coupled receptors: the promise and the challenges—a medicinal chemistry perspective
Med. Res. Rev.
Cannabinoid receptor localization in brain
Proc. Natl. Acad. Sci. U.S.A.
CB1 receptor localization in rat spinal cord and roots, dorsal root ganglion, and peripheral nerve
Zhongguo Yao Li Xue Bao
Molecular characterization of a peripheral receptor for cannabinoids
Nature
From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology
Physiol. Rev.
Novel cannabinoid receptors
Br. J. Pharmacol.
Terpenes and lipids of the endocannabinoid and transient-receptor-potential-channel biosignaling systems
ACS Chem. Neurosci.
Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice
Mol. Pharmacol.
Hypothalamic CB1 cannabinoid receptors regulate energy balance in mice
Endocrinology
Evidence for a cannabinoid receptor in immunomodulation by cannabinoid compounds
Adv. Exp. Med. Biol.
CB2 receptors in reproduction
Br. J. Pharmacol.
Cited by (59)
Organocatalytic Enantioselective Syntheses of Flavonoids and Cannabinoids
2024, Advanced Synthesis and CatalysisDevelopment of Yin-Yang ligand for cannabinoid receptors
2023, Bioorganic ChemistryCannabidiol decreases motivation for cocaine in a behavioral economics paradigm but does not prevent incubation of craving in mice
2022, Biomedicine and PharmacotherapyUntapped endocannabinoid pharmacological targets: Pipe dream or pipeline?
2021, Pharmacology Biochemistry and BehaviorCitation Excerpt :Biased agonists are being explored as a way to circumvent beta-arrestin signaling, thereby theoretically decreasing the likelihood that the development of tolerance will occur. In an update to the review by Mallipeddi et al. (2017) over biased cannabinoid compounds, two notable preclinical studies have yielded further evidence that merits discussion regarding the development of biased cannabinoid therapeutics. A study by Ford and colleagues detailed a new CB1R biased agonist, (Z)-2-((1-(4-fluorobenzyl)-1H-indol-3-yl)methylene)quinuclidin-3-one (PNR-4-20).
Structural and Functional Insights into Cannabinoid Receptors
2020, Trends in Pharmacological SciencesCitation Excerpt :CB2 is an attractive therapeutic target forinflammatory, neuropathic pain, neuroinflammation, tranquilization, and neurodegenerative disorders [22–25]. Of agonists binding to cannabinoid receptors, either CB1 or CB2 preferentially couples to the Gi proteins, although it is reported that CB1 also couples with Gs or Gq proteins under certain conditions, such as in the cultured rat striatal neurons, and mouse hippocampal neurons treated with agonist WIN 55,212-2 [15,26]. Activated cannabinoid receptors are transformed to diverse conformations and provoke the specific downstream signaling via the coupling of different G proteins, for example, Gαi binding results in the inhibition of adenylyl cyclase (AC) and consequently the decrease of cAMP production [27], or activates the mitogen-activated protein kinase cascade to modulate gene expression, to participate in subsequent physiological and pathological events [28].